Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Vera Therapeutics (NASDAQ:VERA) had its target price lifted by research analysts at HC Wainwright from $90.00 to $110.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 179.90% from the company’s current price.

A number of other equities analysts also recently commented on the stock. The Goldman Sachs Group upped their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Wedbush boosted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Bank of America upped their target price on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $80.80.

Vera Therapeutics Stock Performance

VERA stock opened at $39.30 on Monday. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $56.05. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -8.43 and a beta of 1.17. The business’s fifty day simple moving average is $45.76 and its two-hundred day simple moving average is $35.95. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the firm earned ($0.72) EPS. Analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insiders Place Their Bets

In other Vera Therapeutics news, SVP Joseph R. Young sold 3,117 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $130,851.66. Following the transaction, the senior vice president owned 64,722 shares in the company, valued at $2,717,029.56. The trade was a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marshall Fordyce sold 16,925 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50. Following the completion of the transaction, the chief executive officer owned 257,163 shares of the company’s stock, valued at $10,795,702.74. This represents a 6.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 33,490 shares of company stock worth $1,405,910. Insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares in the last quarter. Optimize Financial Inc grew its holdings in Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after purchasing an additional 256 shares during the last quarter. Virtus Investment Advisers LLC increased its position in shares of Vera Therapeutics by 5.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after purchasing an additional 424 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after purchasing an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.